Minal Atul Barve MD (She/Her)

[Pronunciation: mee-nul, bar-vay ]

Oncology•Dallas, TX

Physician

Join to View Full Profile

8196 Walnut Hill LnSte 100Dallas, TX 75231
Phone+1 214-739-4175
Fax+1 214-987-4161

Education & Training

Baylor University Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2003
Texas Health Resources (Dallas)Residency, Internal Medicine, 1996 - 1999
Dr P Deshmukh Mem Medicine Coll, Amravati UniversityClass of 1993

Certifications & Licensure

TX State Medical License 2000 - 2026
CO State Medical License 1999 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Salvage Ovarian FANG™ Vaccine + Carboplatinum Start of enrollment: 2013 Jun 01
Completed
Phase 2
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Start of enrollment: 2016 Feb 10
Completed
Phase 2
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers Start of enrollment: 2016 Jun 03
Completed
Phase 2
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies Start of enrollment: 2019 May 17
COMPLETED
PHASE1
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Start of enrollment: 2021 Sep 09
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Contact
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Start of enrollment: 2022 May 31
RECRUITING
PHASE1
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas Start of enrollment: 2022 Mar 28
RECRUITING
PHASE1
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors Start of enrollment: 2022 Jun 20
SUSPENDED
PHASE1
TH1902 in Patients With Advanced Solid Tumors Start of enrollment: 2021 Mar 04
ACTIVE_NOT_RECRUITING
PHASE1
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers Start of enrollment: 2020 Sep 23
TERMINATED
PHASE1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors Start of enrollment: 2021 Aug 18
RECRUITING
PHASE1
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) Start of enrollment: 2021 Jul 02
RECRUITING
PHASE1
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Start of enrollment: 2021 Jan 18
RECRUITING
PHASE2
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Start of enrollment: 2023 Dec 28
TERMINATED
PHASE1
Join now to see all

Publications & Presentations

PubMed

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes, Asim Amin, Christopher D Lao
Clinical Cancer Research. 2025-10-01
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study.
Nirav N Shah, Pier Luigi Zinzani, Michael L Wang, Sunita D Nasta, Ewa Lech-Maranda
Blood Advances. 2025-08-22
4 citations
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors WithAlterations: A Phase Ia Dose-Escalation Study.
John V Heymach, Frans Opdam, Minal Barve, Hai-Yan Tu, Yi-Long Wu
Journal of Clinical Oncology. 2025-04-10

Press Mentions

Drug Combinations and New Approvals Delivering Optimistic Results in Oncology StocksDecember 8th, 2021
Gradalis®, Inc. Announces Dosing of First Patient in Pilot Study Combining Vigil® Engineered Autologous Tumor Cell Immunotherapy and Durvalumab in Advanced Breast CancerAugust 29th, 2016

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Hindi, Marathi